An Extension Study of Iron Chelation Therapy With Deferasirox (ICL670) in β-thalassemia Patients With Transfusional Iron Overload

Inclusion Criteria

• •Patients who completed the 12-month core study (NCT00061750)
• •Female patients after menarche and who were sexually active, if they used double-barrier contraception, oral contraceptive plus barrier contraceptive, or had undergone clinically documented total hysterectomy and/or ovariectomy, or tubal ligation
• •Written informed consent obtained from the patient and/or legal guardian on the patient's behalf in accordance with the national legislation